CD95-mediated tumor recognition by CD4(+) effector cells in a murine mammary model

Citation
E. Aruga et al., CD95-mediated tumor recognition by CD4(+) effector cells in a murine mammary model, J IMMUNOTH, 23(2), 2000, pp. 225-234
Citations number
29
Categorie Soggetti
Immunology
Journal title
JOURNAL OF IMMUNOTHERAPY
ISSN journal
15249557 → ACNP
Volume
23
Issue
2
Year of publication
2000
Pages
225 - 234
Database
ISI
SICI code
1524-9557(200003/04)23:2<225:CTRBCE>2.0.ZU;2-K
Abstract
The authors examined cellular mechanisms involved in anti-tumor reactivity induced by the murine MT-9GI mammary tumor line, which was transduced to se crete granulocyte macrophage-colony-stimulating factor (GM-CSF). Compared w ith the parental MT-901 tumor, MT-9G1 subcutaneous tumors elicited an influ x of CD4(+) cells and dendritic cells. Secondary in vitro activation of tum or-draining lymph node cells with anti-CDS and interleukin-2 resulted in ef fector cells that can mediate regression of established pulmonary metastase s after adoptive transfer. In vivo depletion of T-cell subsets showed that tumor regression required CD4(+) tumor-draining lymph node cells rather tha n CD8(+) cells. The activated CD4(+) cells expressed CD95L and mediated lys is of CD95(+) MT-901 tumor cells, which were major histocompatibility compl ex class II negative. The CD4(+) cells also released GM-CSF in response to tumor stimulation. A Fas fusion protein inhibited tumor lysis and GM-CSF re lease by the CD4(+) cells. These studies document an alternate pathway by w hich CD4(+) immune cells may recognize major histocompatibility complex cla ss II-deficient tumors in which CD95L-bearing T cells induced an anti-tumor response mediated via CD95L:CD95.